A recent antitrust verdict has prompted Takeda to revise its 2025 financials, putting the drugmaker at a 152 billion Japanese yen ($949.37 million) loss for the fiscal year. | The company adjusted its full-year 2025 earnings to account for a legal provision of 402.5 billion JPY ($2.5 billion).
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Takeda plans to appeal after a federal jury found it liable in a landmark pay-for-delay antitrust case and ordered the Japanese…
Takeda confirmed it would appeal the outcome, stating that the case “lacks merit”.
Takeda has updated its financial results to reflect costs it could incur after losing an antitrust lawsuit concerning its…
With a new CEO prepared to take the reins next month and three key launches on deck for 2026 and 2027, Takeda is ready to shake…
Takeda faces nearly $885 million jury verdict in AMITIZA antitrust case and plans post-trial motions and appeal.
Japanese drugmaker was accused by US pharmacies, retailers of 'pay-for-delay' scheme
